BDBM247417 US10336754, Example 371::US11053247, Example 371::US9453018, 370::US9453018, 371

SMILES C[C@@H]1CCC[C@@H](c2ccnc(c2)-c2c(NC1=O)cnn2C)n1cnc(cc1=O)-c1cc(Cl)ccc1-n1cc(nn1)C(F)(F)F

InChI Key InChIKey=FQRJWJILLRZDIQ-MWTRTKDXSA-N

Data  12 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 247417   

TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nM ΔG°:  -14.2kcal/molepH: 7.4 T: 2°CAssay Description:Factor XIa determinations were made in 50 mM HEPES buffer at pH 7.4 containing 145 mM NaCl, 5 mM KCl, and 0.1% PEG 8000 (polyethylene glycol; JT Bake...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nM ΔG°:  -14.2kcal/molepH: 7.4 T: 2°CAssay Description:Factor XIa determinations were made in 50 mM HEPES buffer at pH 7.4 containing 145 mM NaCl, 5 mM KCl, and 0.1% PEG 8000 (polyethylene glycol; JT Bake...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nMAssay Description:Factor XIa determinations were made in 50 mM HEPES buffer at pH 7.4 containing 145 mM NaCl, 5 mM KCl, and 0.1% PEG 8000 (polyethylene glycol; JT Bake...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nMAssay Description:Factor XIa determinations were made in 50 mM HEPES buffer at pH 7.4 containing 145 mM NaCl, 5 mM KCl, and 0.1% PEG 8000 (polyethylene glycol; JT Bake...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  0.100nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  17nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  17nMAssay Description:Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  17nM ΔG°:  -11.0kcal/molepH: 7.5 T: 2°CAssay Description:Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  19nMAssay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  19nMAssay Description:Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM247417(US10336754, Example 371 | US11053247, Example 371 ...)
Affinity DataKi:  19nM ΔG°:  -10.9kcal/molepH: 7.5 T: 2°CAssay Description:Plasma kallikrein determinations were made in 0.1 M sodium phosphate buffer at a pH of 7.5 containing 0.1-0.2 M sodium chloride and 0.5% PEG 8000. De...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent